Melanoma is a neoplasm that originates from melanocytes, pigment-producing cells in the skin. Melanoma is a relatively, immunogenic tumour, as demonstrated by the presence of both cytotoxic T lymphocytes (CTLs) and antibodies (Mattes et al., 1983; Knuth et al., 1992) in melanoma patients that react with melanoma tumour cells. The availability of antibodies and CTLs with anti-melanoma reactivity allowed the identification of several tumour-associated antigens. These include tumour-specific antigens and melanocyte differentiation antigens that are expressed by melanoma tumour cells as well as by normal melanocytes and retina (van der Bruggen et al., 1991; Brichard et al., 1993; Vijayasaradhi et al., 1990; Bakker et al., 1994; Kawakami et al., 1994a,b; Coulie et al., 1994; Gaugler et al., 1994 and Wang et al., 1995). Identification of the antigens recognised by anti-tumour CTL is important for understanding the molecular basis of tumour recognition by T cells and may lead to the development of new immunotherapeutical strategies to treat cancer patients.

Recently, we cloned the cDNA encoding the melanocyte lineage-specific antigen gp100 and demonstrated that gp100 is recognised by three different MAbs used to diagnose malignant melanoma, NKI-beteb, HMB-45 and HMB-50 (Adema et al., 1993, 1994). In addition, we demonstrated that gp100 is recognised by a tumour-infiltrating T-cell line (TIL 1200), isolated from a melanoma patient (Bakker et al., 1994). Molecular characterisation of the cDNA encoding gp100 revealed that it is a type I transmembrane glycoprotein of 641 amino acids highly homologous to another melanocyte-specific protein, pMel17 (Adema et al., 1994; Kwon et al., 1991). Nucleotide sequence analysis of genomic DNA indicated that the transcripts corresponding to gp100 and pMel17 cDNAs originate from a single gene via alternative splicing. The difference between gp100 and pMel17 consists of a stretch of seven amino acids in the carboxy terminal part of pMel17 (position 567; Adema et al., 1994) that is absent in gp100. In all normal and malignant melanocytic cells expressing the gp100/pMel17 gene, gp100 and pMel17 mRNAs are expressed simultaneously.

Here, we demonstrate that pMel17, like gp100, is recognised by all three MAbs used to diagnose malignant melanoma and is properly processed and presented to anti-melanoma tumour-infiltrating lymphocytes.

Summary

Recently, we cloned the cDNA encoding the melanocyte lineage-specific antigen gp100 and demonstrated that gp100 is recognised by three different monoclonal antibodies (MAbs) used to diagnose malignant melanoma. In addition, we showed that tumour-infiltrating lymphocytes (TIL 1200) from a melanoma patient reacted specifically with cells transfected with the gp100 cDNA. Molecular characterisation of the gp100 cDNA revealed that the gp100 antigen is highly homologous, but not identical, to another melanocyte-specific protein, pMel17. Here, we report that cells transfected with pMel17 cDNA also react with all three MAbs used to diagnose malignant melanoma, NKI-beteb, HMB-45 and HMB-50. Moreover, pMel17 transfectants are specifically lysed by TIL1200. These data demonstrate that antigenic processing of both gp100 and pMel17 give rise to peptides seen by anti-melanoma cytotoxic T lymphocytes (CTL) and are therefore potential targets for immunotherapy of malignant melanoma.

Keywords: melanoma; gp100/pMel17; cytotoxic T cell; NKI-beteb

Materials and methods

Cells and monoclonal antibodies

Culturing of the melanoma cell lines MEWO, BLM and of COS-7 cells has been described previously (Adema et al., 1993, 1994). TIL 1200 was generated from a metastatic melanoma and cultured with 1000 U ml⁻¹ interleukin-2 (IL-2) (Cetus Corp., Emeryville, CA, USA) as described previously (Kawakami et al., 1992). NKI-beteb and HMB-50 have been described previously (Vennegoor et al., 1988; Vogel and Esclamado, 1988). HMB-45 was purchased from Enzo Biochem.

Molecular cloning and nucleotide sequence analysis

Using a reverse transcriptase-polymerase chain reaction (PCR) (GeneAmp kit, Perkin elmer, the Netherlands) approach with 5'-ctgcatggagatcttcatcg-3' as the 5' primer and 5'-tcttgagtctcagaaaataacagacat-3' as the 3' primer we isolated the 3' part of pMel17 cDNA from total RNA isolated from the melanoma cell line MEWO. The PCR product was used to replace the 3' part of the gp100 cDNA as present in pSVLgp100+ (Adema et al., 1994) using BglII and the newly created SalI site in the 3' primer (underlined). The resulting construct, pSVLpMel17, was sequenced by the dideoxy-nucleotide sequencing method using T7 DNA polymerase (Pharmacia, Woerden, The Netherlands). pCMVneo pMel17 was constructed by cloning the complete pMel17 cDNA from pSVLpMel17 as a blunt-ended Xhel–SalI fragment in the blunt-ended BamHI site of pCMVneo (Bakker et al., 1994).

Transfections and immunostaining

Transient expression of DNA constructs in COS-7 cells was performed using 40 µg ml⁻¹ lipofectin reagent (BRL, Gaithersburg, MD, USA) and 7.5 µg of DNA. BLM cells were transfected with 20 µg of pCMVneo pMel17 DNA using calcium phosphate transfection systems (BRL, Gaithersburg, MD, USA) and stable clones were isolated by G418 selection (1 mg ml⁻¹) as previously described (Bakker et al., 1994).
Transfected cells were prepared for immunofluorescence using FITC-conjugated GAM-IgG-F(ab')$_2$ (Zymed, San Francisco, CA, USA) as described previously (Adema et al., 1993) and examined using confocal laser scanning microscope at 488 nm (Biorad MRC 600).

**Metabolic labelling and immunoprecipitations**

Immunoprecipitation experiments were performed on metabolically labelled (L-[35S]methionine/cysteine; Amersham) cells as described by Vennegoor et al. (1988) using either NKI-beteb or HMB-50 covalently linked to protein A-CL 4B sepharose beads (Pharmacia, Uppsala, The Netherlands). Immunoprecipitates were analysed under reducing conditions by SDS-PAGE using 5–17.5% gradient gels. The relative molecular weight of the proteins was determined using co-electrophoresised, prestained markers (BRL, Gaithersburg, MD, USA). Gels were treated with 1 M sodium selenate (pH 5.4) before autoradiography (Kodak XAR).

**Chromium-release assay**

Chromium release assays were performed as described previously (Bakker et al., 1994). Briefly, 10$^5$ target cells were incubated with 100 μCi $^{51}$Cr sodium chromate (Amerham, Buckingham, UK) for 1 h. Various amounts of effector cells were then added to 2 × 10$^5$ target cells in triplicate wells of U-bottomed microtitre plates (Costar, Badhoevedorp, The Netherlands) in a final volume of 150 μl. After 5 h of incubation part of the supernatant was harvested and its radioactive content was measured.

**Results**

The gp100/pMel17 gene encodes both gp100 and pMel17 mRNA as a consequence of alternative RNA processing. The pMel17 mRNA encodes a stretch of seven amino acids not encoded by the gp100 mRNA (Figure 1). To investigate the immunological properties of pMel17 we constructed a cDNA. Using an RT-PCR approach we first cloned the 3' part of the pMel17 cDNA encoding the carboxy terminal part of pMel17, including the additional seven amino acids absent in gp100. Nucleotide sequence analysis of the 3' part confirmed the presence of the nucleotide sequence...
encoding the pMel17-specific amino acids. In addition, we found pMel17 cDNAs containing either a thymidine (as in the gp100 cDNA; Adema et al., 1994) or a cytosine at position 1998. This nucleotide change does not result in an amino acid substitution. The finding that the same nucleotide difference was found in a gp100 cDNA clone isolated from the same cell line, indicates that this particular cell line contains two different alleles of the gp100/pMel17 gene. Subsequently, we created a full length pMel17 cDNA by exchanging the 3' part of the gp100 cDNA with the 3' part of pMel17 cDNA.

To investigate whether the difference between gp100 and pMel17 affects recognition by the anti-gp100 MAbs NKI-beteb, HMB-45 and HMB-50, we transfected the cDNA encoding pMel17 into the gp100/pMel17 negative melanoma cell line BLM. As shown in Figure 2, expression of the pMel17 cDNA resulted in immunoreactivity with all three MAbs. The typical speckled staining pattern of the pMel17 transfectants was identical to that previously observed for gp100, suggesting that pMel17, like gp100, localises in melanosomes. Immunoreactivity with all three MAbs was also observed when pMel17-CDNA was transiently expressed in non-melanocytic COS-7 cells (data not shown). We also analysed the pMel17 protein detected by MAbs NKI-beteb or HMB-50 in COS-7 cells transfected with the pMel17 cDNA using immunoprecipitation reactions. As shown in Figure 3, the pMel17 protein co-migrates with the gp100 protein immunoprecipitated from MEWO melanoma cells. The slight difference in mobility between transfected COS-7 cells and MEWO melanoma cells, which express both gp100 and pMel17 endogenously, has previously been shown to be due to differential glycosylation (Adema et al., 1994). Collectively, these data demonstrate that the difference between gp100 and pMel17 does not affect recognition by either of the MAbs used to diagnose malignant melanoma. NKI-beteb, HMB-50 and HMB-45. The data describing the specificity of these MAbs for cells of the melanocytic lineage can therefore be extrapolated to the expression of pMel17.

Previously, we showed that gp100 is recognised by tumour-infiltrating lymphocytes, (TIL)1200, isolated from a melanoma patient in an HLA-A2.1 restricted manner (Bakker et al., 1994). To investigate whether the pMel17 antigen also gives rise to peptide epitopes that gain access to the MHC class I antigen presentation pathway, we determined the cytolytic activity of TIL 1200 against HLA-A2.1 + BLM cells transfected with the pMel17 cDNA. As demonstrated in Figure 4, the pMel17 transfectants were efficiently lysed by TIL 1200. No specific lysis was observed using the parental, untransfected BLM cells or BLM cells transfected with the expression vector without an insert (not shown). These data demonstrate that peptide epitope(s) recognised by TIL 1200 are properly processed from the pMel17 protein and presented in the context of HLA-A2.1. Two gp100-derived peptides (corresponding to the amino acids at positions 154-162 and 457-466) have been identified that are recognised by TIL 1200 (Bakker et al., 1995; Kawakami et al., 1995). These peptides are located in the common part between gp100 and pMel17. Since TIL 1200 is an oligoclonal, CD8+ T-cell line expressing a restricted number of T-cell receptors (Shilyanski et al., 1994), it is most likely that either one or both of the aforementioned immunogenic peptides are responsible for the observed lysis of the pMel17 and gp100 transfecteds.

![Figure 3](image3.png)

**Figure 3** The pMel17 protein is recognised by NKI-beteb and HMB-50 in extracts from pSVLpMel17 transfected COS-7 cells. MEWO cells (MEWO) and COS-7 cells transfected with either pSVLpMel17 (pMel17), pSVLgp100 (gp100) or with a construct encoding the gp100 cDNA in the non-coding orientation (Mock) were metabolically labelled and subjected to immunoprecipitations using NKI-beteb (NKI), HMB-50 (50) or normal mouse serum (NMS) as indicated above each lane. Immunoprecipitated proteins were analysed under reducing conditions by SDS-PAGE (linear gradient of 5–17% acrylamide) and visualised by autoradiography. The position and size (kDa) of prestained molecular weight markers are indicated.

![Figure 4](image4.png)

**Figure 4** Lysis of HLA-A2.1 + pMel17 transfectants by TIL1200. BLM cells transfected with pCMVneoMel17, pCMVneoGP100, the parental BLM cells and the gp100/pMel17 positive Mel624 cells were tested for sensitivity to lysis by TIL1200. One representative experiment with the stable pMel17 transfected clone AB1 is shown. -Δ-, BLM; -▪-, Mel624; -●- BLM gp100 H23; -□-, BLM pMel17 AB1.
The finding that not only gp100 but also pMel17 is recognised by TIL1200 in the common part of the melanocyte lineage. The identical staining pattern observed with the MAbs in gp100 and pMel17 transfectants further indicates that, like gp100, pMel17 is also present in melanomas, which is in line with their proposed role in the process of pigmentation (Kwon et al., 1991). Whether there exists a functional difference between gp100 and pMel17 remains to be determined. The relative immunogenicity of melanoma tumours has long been recognised. Both cytotoxic T cells and MAbs have been identified that specifically recognise melanoma tumour cells. So far, a number of the antigens recognised have been classified in detail. They include the tumour-specific proteins, MAGE-1 (van der Bruggen et al., 1991) and MAGE-3 (Gaugler et al., 1994), which are expressed in different types of tumour cells and in tests. In addition, the melanocyte differentiation antigens tyrosinase, gp100, Melan-A/MART-1 and gp75 (Briehard et al., 1993; Bakker et al., 1994; Kawakami et al., 1994a;b; Coulie et al., 1994; Wang et al., 1995) that are expressed in normal and malignant melanocytes as well as in retina have been identified as targets for anti-melanoma CTLs. Potentially, these antigens are targets for specific immunotherapy.

TIL1200 was isolated from a melanoma metastasis and was shown to recognise the melanocyte differentiation antigen gp100. Interestingly, reinfusion of in vitro expanded TIL1200 together with IL-2 in the autologous patient resulted in objective tumour regression (Kawakami et al., 1994a,b). Here we demonstrate that TIL1200 not only recognises the gp100 antigen, but also the pMel17 antigen that is encoded by an mRNA species derived from the same gene via alternative splicing. Since we have previously shown that melanoma cells express gp100 and pMel17 mRNA simultaneously, both proteins contribute to the total amount of immunogenic peptides presented in the context of HLA-A2.1 that are recognised by TIL1200. This finding is also consistent with the recent mapping of two peptide epitopes (corresponding to the amino acids at positions, 154 -162 and 457 -466) recognised by TIL1200 in the common part of gp100 and pMel17 (Bakker et al., 1995; Kawakami et al., 1995 and Figure 5). Although it has been observed that sequence context can affect processing and/or presentation of T-cell epitopes (Eisenlohr et al., 1992; Del Val et al., 1991), this does not seem to be the case for pMel17 and gp100. The fact that TIL1200 is an oligoelonal, CD8+ T-cell line expressing a restricted number of T-cell receptors (Shilianski et al., 1994), implies that either one or both these epitopes are properly processed from the pMel17 antigen and presented by HLA-A2.1. Attempts to further investigate the recognition of the pMel17 epitopes using cloned TIL have not been successful.

Besides TIL1200, other CTL1-recoquilising distinct epitopes encoded by the gp100/pMel17 have recently been characterised (Cox et al., 1994; Kawakami et al., 1995). A total of five distinct peptides have now been identified (Figure 5), all of which are present in both gp100 and pMel17, and are presented by the same restriction element, HLA-A2.1. Examination of the additional amino acid sequence present

Figure 5 Amino acid sequence of the pMel17 antigen (including signal peptide) and location of the peptide epitopes. The peptide epitopes as recognised in the gp100 antigen are underlined [Bakker et al., 1995], Kawakami et al. (1995), Cox et al. (1994); the amino acids uniquely present in pMel17 are in italic capitals.
in pMe17 revealed that six peptides (including 9- and 10-mers) bearing the HLA-A2.1 binding motif are uniquely present in pMe17, whereas three peptides are specifically present in gp100 (Figure 1). HLA-A2.1 stabilisation experiments revealed that two of the pMe17-specific peptides listed in Figure 1 bind to HLA-A2.1 (ABHB and C1A; unpublished observation). When analysing immunoreactivity against the products of the gp100/pMe17 gene, one should therefore include both gp100 and pMe17.

In conclusion, the data presented in this report demonstrate that pMe17 is recognised by three different MABs used to diagnose melanoma and functions as a target for anti-melanoma CTLs.

Acknowledgements

We would like to thank Dr Y Kawakami (Surgery Branch, NIH, Bethesda, USA) for providing TIL1200 and Ms M Meijer for secretarial help. This work was supported by the Dutch Cancer Society.

References


